{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"Number of Participants who experienced grade 3 or higher Adverse Events during the first 100 days of the transplant.","groups":[{"description":"Patients receive panobinostat PO QD on days -9 to -2, gemcitabine hydrochloride IV over 4 hours on days -8 and -3, busulfan IV over 3 hours on days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo autologous peripheral blood stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous peripheral blood stem cell transplant\n\nBusulfan: Given IV\n\nGemcitabine Hydrochloride: Given IV\n\nMelphalan: Given IV\n\nPanobinostat: Given PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo autologous peripheral blood stem cell transplant\n\nPharmacological Study: Correlative studies","id":"OG000","title":"Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel"},{"description":"Patients receive panobinostat PO QD on days -9 to -2, gemcitabine hydrochloride IV over 4 hours on days -8 and -3, busulfan IV over 3 hours on days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo autologous peripheral blood stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous peripheral blood stem cell transplant\n\nBusulfan: Given IV\n\nGemcitabine Hydrochloride: Given IV\n\nMelphalan: Given IV\n\nPanobinostat: Given PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo autologous peripheral blood stem cell transplant\n\nPharmacological Study: Correlative studies","id":"OG001","title":"Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to day 100","title":"Participants Who Experienced Grade 3 or Higher Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}